Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

por Spinosa-Guzman, S, Van de Casteele, T, De La Rosa, G, De Doncker, P
Publicado 2010

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir

por Overton, T, Aberg, JA, Gupta, S, Ryan, R, Baugh, B, De La Rosa, G
Publicado 2010

Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009

por De La Rosa, G, Pattery, T, Picchio, G, Lathouwers, E, Villacian, J, Van der Borght , K
Publicado 2010

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

por Sekar, V, De La Rosa, G, Van de Casteele, T, Spinosa-Guzman, S, Vis, P, Hoetelmans, RMW
Publicado 2010

Gold Binding by Native and Chemically Modified Hops Biomasses

por López, M. Laura, Gardea-Torresdey, J. L., Peralta-Videa, J. R., de la Rosa, G., Armendáriz, V., Herrera, I., Troiani, H., Henning, J.
Publicado 2005